Sugi Predict

Sugi Predict / Compounds / SCHEMBL917596

SCHEMBL917596

SCHEMBL917596

CC(C)(C)OC(=O)N1CC(O)C(O)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.56
▸ USP2 O75604 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CHRM2 P08172 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ EPHX2 P34913 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72800 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL71583 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL666524 1.00 NR1H2 (0.56) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL30287755 0.92 NR1H2 (0.53) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL2441060 0.92 NR1H2 (0.53) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL2441058 0.92 NR1H2 (0.53) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL19420219 0.92 NR1H2 (0.53) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL23288691 0.90 NR1H2 (0.51) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL951953 0.90 NR1H2 (0.51) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL951952 0.90 NR1H2 (0.51) NR1H2USP2SMN1; SMN2CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001876-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2026-01-01 — — US disclosed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 — — US disclosed
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-07-24 — — US disclosed
EP-4572761-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 — — EP disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 — — EP disclosed
WO-2025111492-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2025-05-30 — — WO disclosed
CN-119730854-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2025-03-28 — — CN disclosed
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-12-31 — — US disclosed
CN-119019369-A Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2024-11-26 — — CN disclosed
CN-115397821-B Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2024-09-03 — — CN disclosed
US-6107329-A HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS PFIZER, INC. (US) 2000-08-22 — — US disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 — — WO disclosed
US-6004956-A CHEMICAL INTERMEDIATES FOR BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-12-21 — — US disclosed
CN-1142492-A Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents PFIZER (US) 1997-02-12 — — CN disclosed
WO-1996039384-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER, INC. (US) 1996-12-12 — — WO disclosed
US-5532364-A FROM A DIHYDROPYRIDINE DERIVATIVE BAYER AKTIENGESELLSCHAFT (DE) 1996-07-02 — — US disclosed
US-5436334-A Enantiomerically pure 2-oxa-5,8-diazabicyclo[4.3.0]nonanes and process for their preparation BAYER AKTIENGESELLSCHAFT (DE) 1995-07-25 — — US disclosed
EP-0151282-B1 OPTICALLY ACTIVE 3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE, RHODIUM COMPLEXES CONTAINING THEM AS CHIRAL LIGANDS, AND THEIR USE Degussa Aktiengesellschaft (DE) 1988-09-07 — — EP disclosed
US-4634775-A HYDROGENATION CATALYSTS FOR ACYLAMINO-ACRYLIC ACIDS DEGUSSA AKTIENGESELLSCHAFT (DE) 1987-01-06 — — US disclosed
EP-0151282-A1 Optically active 3,4-bis-(diphenylphosphino)-pyrrolidine, rhodium complexes containing them as chiral ligands, and their use Degussa Aktiengesellschaft (DE) 1985-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001876-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE7A NR1H2 1265/4885USP2 3709/4885SMN1; SMN2 1001/4885
US-12180193-B2 Accelerating fibrosarcoma protein degrading compounds and associated methods of use CRBN, RBX1, ARAF NR1H2 3971/4885USP2 43/4885SMN1; SMN2 2911/4885
US-20250236612-A1 RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE CRBN, RBX1, ARAF NR1H2 3984/4885USP2 43/4885SMN1; SMN2 2861/4885
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B NR1H2 883/4885USP2 3689/4885SMN1; SMN2 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.